Novartis AG (NVSEF) stock
NVSEFOTCPharmaceutical PreparationsFiscal year ends December 31Also trades as NVS
$146.46+2.56 (+1.78%)
Close on Oct 19, 2026Market cap $279.46BP/E 20.5Yield –
Novartis gross profit
Gross profit is revenue minus the direct cost of the goods and services sold.
For fiscal 2025 it was $42.98B, up 10.5% from the year before. Over ten years it grew 2.7% a year on average. The highest annual figure on record is $42.98B in fiscal 2025.
Annual gross profit
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $42.98B | +10.5% |
| FY2024 | Dec 31, 2024 | $38.90B | +13.8% |
| FY2023 | Dec 31, 2023 | $34.19B | +7.2% |
| FY2022 | Dec 31, 2022 | $31.88B | -1.1% |
| FY2021 | Dec 31, 2021 | $32.24B | -7.3% |
| FY2020 | Dec 31, 2020 | $34.78B | +1.5% |
| FY2019 | Dec 31, 2019 | $34.25B | +8.4% |
| FY2018 | Dec 31, 2018 | $31.59B | +6.1% |
| FY2017 | Dec 31, 2017 | $29.77B | -6.7% |
| FY2016 | Dec 31, 2016 | $31.92B | -3.2% |
| FY2015 | Dec 31, 2015 | $32.98B | – |
Quarterly gross profit
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $11.24B | +20.4% |
| Q2 FY2025 | Jun 30, 2025 | $11.51B | +22.8% |
| Q2 FY2024 | Jun 30, 2024 | $9.70B | +18.4% |
| Q2 FY2023 | Jun 30, 2023 | $8.40B | -2.5% |
| Q2 FY2022 | Jun 30, 2022 | $9.33B | +15.3% |
| Q2 FY2021 | Jun 30, 2021 | $9.38B | +13.9% |
| Q2 FY2020 | Jun 30, 2020 | $8.19B | – |
| Q2 FY2019 | Jun 30, 2019 | $8.62B | – |
| Q2 FY2018 | Jun 30, 2018 | $8.10B | – |
| Q2 FY2017 | Jun 30, 2017 | $8.24B | – |
See a number that looks wrong?